Business
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1TM gene therapy for patients with inadequately controlled T2D and obesity Expect to dose first patients and report preliminary data in 2026, pending CTA authorization BURLINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company pioneering pattern-breaking treatments for obesity and type 2 diabetes (T2D),
About this update from Fractyl Health, Inc.
[{"type":"image","alt":"Fractyl Health, Inc.","displaySize":"","headline":null,"caption":"Fractyl Health, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":104,"url":"https://media.zenfs.com/en/globenewswire.com/9ee0df9b33cb03fd3cc1257160c381e5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/grE4KlKD7t64vNihlXguCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9ee0df9b33cb03fd3cc1257160c381e5","width":300,"height":104}},"lazy":false},{"type":"text","content":"First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1TM gene therapy for patients with inadequately controlled T2D and obesity","length":193,"tagName":"p"},{"type":"text","content":"Expect to dose first patients and report preliminary data in 2026, pending CTA authorization","length":92,"tagName":"p"},{"type":"text","content":"BURLINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company pioneering pattern-breaking treatments for obesity and type 2 diabetes (T2D), today announced that it has submitted the first module of its Clinical Trial Application (CTA) in Europe for RJVA-001, the Company’s gene therapy candidate from its Rejuva platform. RJVA-001 is designed to express glucagon-like peptide-1 (GLP-1) locally in pancreatic beta cells using nutrient-responsive control, potentially enabling physiologic hormone secretion without the high circulating levels that contribute to side effects seen with systemic GLP-1 drug therapy. Pending regulatory clearance, Fractyl anticipates initiating first-in-human dosing and reporting preliminary data in 2026.","length":808,"tagName":"p"},{"type":"text","content":"RJVA-001 is delivered via a one-time, minimally invasive endoscopic ultrasound-guided infusion directly into the pancreas. The gene therapy construct is designed to harness a proprietary, engineered version of the human insulin promoter and trafficking signals that allow for nutrient-triggered secretion of GLP-1 from transduced pancreatic beta cells—offering a “smart,” physiologic alternative to chronic pharmacotherapy. RJVA-001 is designed to enable the physiologic hormone signaling of GLP-1 through native metabolic circuits in the gut and portal vein rather than relying...